Regency Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Regency Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-675	Closed	-$52K	–	46
2022 Q2	$52K	Hold	675	–	–	0.06%	55
2022 Q1	$49K	Hold	675	–	–	0.04%	72
2021 Q4	$42K	Hold	675	–	–	0.03%	84
2021 Q3	$40K	Hold	675	–	–	0.03%	89
2021 Q2	$45K	Hold	675	–	–	0.03%	83
2021 Q1	$43K	Buy	+675	New	+$42K	0.05%	93

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regency Capital Management's BMY Position: Q3 2022 in Review

Regency Capital Management sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 675 shares — an estimated $52K sold.

Regency Capital Management first reported a position in BMY in Q1 2021 and held it in 6 quarters. The position peaked at $52K in Q2 2022. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

Regency Capital Management reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
Regency Capital Management sold 675 Bristol-Myers Squibb shares in Q3 2022, an estimated $52K.
Regency Capital Management first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 6 quarters.
Regency Capital Management's Bristol-Myers Squibb position peaked at $52K in Q2 2022.
2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Regency Capital Management's 13F filing for Q3 2022, filed 4 Nov 2022.